HC Wainwright Forecasts Strong Price Appreciation for argenx (NASDAQ:ARGX) Stock

argenx (NASDAQ:ARGX) had its price objective upped by equities researchers at HC Wainwright from $717.00 to $720.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 15.26% from the company’s current price. HC Wainwright also issued estimates for argenx’s Q3 2025 earnings at $1.68 EPS and FY2025 earnings at $6.50 EPS.

Several other research analysts have also weighed in on the company. Robert W. Baird lowered argenx from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. JPMorgan Chase & Co. raised their price objective on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Finally, Guggenheim raised their price objective on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $661.17.

argenx Trading Down 0.0 %

Shares of ARGX opened at $624.67 on Friday. The firm has a market capitalization of $37.96 billion, a P/E ratio of -709.85 and a beta of 0.58. The stock’s fifty day simple moving average is $642.62 and its 200 day simple moving average is $590.74. argenx has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Sell-side analysts predict that argenx will post 3.13 earnings per share for the current year.

Hedge Funds Weigh In On argenx

A number of hedge funds have recently bought and sold shares of ARGX. GeoWealth Management LLC boosted its stake in argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after acquiring an additional 18 shares during the period. Whipplewood Advisors LLC bought a new stake in argenx during the fourth quarter worth approximately $37,000. Global Retirement Partners LLC raised its holdings in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares in the last quarter. FIL Ltd bought a new position in shares of argenx in the fourth quarter valued at $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of argenx in the fourth quarter valued at $38,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.